Discordant timing between clinical improvement and changes in neuro‐ophthalmological surrogate markers has frequently been reported in IIH RCTs and real‐world studies, with longitudinal data on Humphrey visual field PMD and OCT measures of RNFL typically demonstrating improvement after a minimum of 12 months of IIH treatment [36, 37]; a fact that may align with the observed reduced risk of papilledema and visual disturbances or blindness with GLP‐1 or GIP/GLP‐1 RA treatment in IIH cohorts with > 12 months of follow‐up [28, 29]. The gene discussed is GCG; the disease is Blindness.